Table 1.
Group A | Group B | P-value | |
---|---|---|---|
(COVID-19 era) | (Pre-COVID-19 era) | ||
(n = 21) | (n = 193) | ||
Age in years, median (range) | 49 (35–82) | 47 (17–80) | 0.58 |
Sex | 0.06 | ||
Male | 14 (66.7%) | 165 (85.5%) | |
Female | 7 (33.3%) | 28 (14.5%) | |
Preoperative chemotherapy | 10 (47.6%) | 71 (36.8%) | 0.35 |
Postponement (number of times) | 12 (57.1%) | 53 (27.5%) | 0.01 |
Tracheostomy | 6 (28.6%) | 13 (6.7%) | 0.005 |
Site | 0.2 | ||
Buccal mucosa | 4 (19.0%) | 55 (28.4%) | |
Hard palate | 0 (0%) | 5 (2.6%) | |
Lower alveolus | 4 (19.0%) | 39 (20.2%) | |
Upper alveolus | 1 (4.8%) | 5 (2.6%) | |
Lip | 2 (9.5%) | 21 (10.9%) | |
Maxilla | 1 (4.8%) | 3 (1.6%) | |
Neck | 0 (0%) | 5 (2.6%) | |
Parotid | 1 (4.8%) | 5 (2.6%) | |
Retromolar trigone | 0 (0%) | 11 (5.7%) | |
Thyroid | 0 (0%) | 17 (8.8%) | |
Tongue | 8 (38.1%) | 27 (14.0%) | |
Flap reconstruction | 7 (33.3%) | 115 (59.6%) | 0.03 |
Hospital stay in days, median (range) | 10 (1–19) | 7 (2–37) | 0.001 |
pT stage | 0.09 | ||
0 | 0 (0%) | 8 (4.1%) | |
1 | 3 (14.3%) | 9 (4.7%) | |
2 | 9 (42.9%) | 48 (24.8%) | |
3 | 2 (9.5%) | 25 (13%) | |
4 | 7 (33.3%) | 103 (53.4%) | |
pN | 0.28 | ||
0 | 9 (42.9%) | 95 (49.2%) | |
1 | 8 (38.1%) | 61 (31.6%) | |
2 | 2 (9.5%) | 32 (16.6%) | |
3 | 2 (9.5%) | 5 (2.6%) | |
Morbidity | 0.57 | ||
Clavien–Dindo grades 3 and 4 | 3 (14.3%) | 41 (21.2%) |
Results are presented as n (%), unless indicated otherwise.